WuXi Advanced Therapies is a global Contract Testing, Development, and Manufacturing Organisation (CTDMO) supporting cell and gene therapy innovation.

WuXi Advanced Therapies provides comprehensive solutions for the discovery, development, and commercialisation of cell and gene therapies. Their capabilities span contract testing, process development, and manufacturing, ensuring quality and regulatory compliance. Based in Philadelphia, with global operations, they support programmes from early development to large-scale commercialisation. WuXi Advanced Therapies is backed by WuXi AppTec, leveraging deep expertise and robust infrastructure to deliver groundbreaking medical advancements.

Key Products and Services:

• Contract Testing: Bioanalytical services, lot release testing, and stability studies.
• Process Development: Scalable solutions for GMP production.
• Manufacturing: Clinical and commercial manufacturing for cell and gene therapies.
• Technologies: TESSA® AAV production and XOFLX™ cell lines.
• Regulatory Services: IND-enabling studies and compliance support.

As one of the top global cell and gene therapy CDMOs, WuXi Advanced Therapies combines innovation with proven expertise to accelerate life-changing therapies. Their integrated approach ensures efficient workflows, quality outcomes, and scalable solutions for advanced therapeutic development. Learn more at WuXi Advanced Therapies.